Finally, we conducted a strictly matched case–control study to compare the clinical efficacy of chemotherapy combined with immunotherapy versus traditional chemotherapy in second-line setting for EGFR mutated NSCLC patients, who progressed on EGFR-TKIs and without the required T790M mutation. Here, EGFR is linked to non-small cell lung carcinoma.